| Comprehensive and integrative genomic characterization of hepatocellular carcinoma A Ally, M Balasundaram, R Carlsen, E Chuah, A Clarke, N Dhalla, RA Holt, ... Cell 169 (7), 1327-1341. e23, 2017 | 1859 | 2017 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1259 | 2018 |
| Comprehensive and integrated genomic characterization of adult soft tissue sarcomas AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ... Cell 171 (4), 950-965, 2017 | 806 | 2017 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 785 | 2015 |
| A pan-cancer proteomic perspective on The Cancer Genome Atlas R Akbani, PKS Ng, HMJ Werner, M Shahmoradgoli, F Zhang, Z Ju, W Liu, ... Nature communications 5 (1), 3887, 2014 | 556 | 2014 |
| A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition MP Mak, P Tong, L Diao, RJ Cardnell, DL Gibbons, WN William, ... Clinical Cancer Research 22 (3), 609-620, 2016 | 432 | 2016 |
| CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li, PA Villalobos, ... Cancer discovery 8 (9), 1156-1175, 2018 | 372 | 2018 |
| MOABS: model based analysis of bisulfite sequencing data D Sun, Y Xi, B Rodriguez, HJ Park, P Tong, M Meong, MA Goodell, W Li Genome biology 15, 1-12, 2014 | 283 | 2014 |
| LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma A Galan-Cobo, P Sitthideatphaiboon, X Qu, A Poteete, MA Pisegna, ... Cancer research 79 (13), 3251-3267, 2019 | 218 | 2019 |
| ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis DH Peng, C Ungewiss, P Tong, LA Byers, J Wang, JR Canales, ... Oncogene 36 (14), 1925-1938, 2017 | 187 | 2017 |
| Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer CA Stewart, P Tong, RJ Cardnell, T Sen, L Li, CM Gay, F Masrorpour, ... Oncotarget 8 (17), 28575, 2017 | 181 | 2017 |
| CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib T Sen, P Tong, CA Stewart, S Cristea, A Valliani, DS Shames, ... Cancer research 77 (14), 3870-3884, 2017 | 172 | 2017 |
| The miR-200 family and the miR-183~ 96~ 182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers ST Kundu, LA Byers, DH Peng, JD Roybal, L Diao, J Wang, P Tong, ... Oncogene 35 (2), 173-186, 2016 | 149 | 2016 |
| A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-β superfamily A Korkut, S Zaidi, RS Kanchi, S Rao, NR Gough, A Schultz, X Li, ... Cell systems 7 (4), 422-437. e7, 2018 | 143 | 2018 |
| A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components MB Nilsson, H Sun, J Robichaux, M Pfeifer, U McDermott, J Travers, ... Science translational medicine 12 (559), eaaz4589, 2020 | 121 | 2020 |
| Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers MB Nilsson, H Sun, L Diao, P Tong, D Liu, L Li, Y Fan, A Poteete, SO Lim, ... Science translational medicine 9 (415), eaao4307, 2017 | 112 | 2017 |
| Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer T Sen, P Tong, L Diao, L Li, Y Fan, J Hoff, JV Heymach, J Wang, LA Byers Clinical Cancer Research 23 (20), 6239-6253, 2017 | 111 | 2017 |
| AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers K Balaji, S Vijayaraghavan, L Diao, P Tong, Y Fan, JPW Carey, TN Bui, ... Molecular Cancer Research 15 (1), 45-58, 2017 | 88 | 2017 |
| High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma TH Ho, IY Park, H Zhao, P Tong, MD Champion, H Yan, FA Monzon, ... Oncogene 35 (12), 1565-1574, 2016 | 88 | 2016 |
| Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and … RJ Cardnell, L Li, T Sen, R Bara, P Tong, J Fujimoto, AS Ireland, ... Oncotarget 8 (43), 73419, 2017 | 82 | 2017 |
